Townsend Richard Nolan's most recent trade in Lexeo Therapeutics Inc. was a trade of 1,074 Common Stock done at an average price of $2.8 . Disclosure was reported to the exchange on May 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 2.77 per share. | 16 May 2025 | 1,074 | 221,173 | - | 2.8 | 2,979 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 2.61 per share. | 14 Mar 2025 | 2,128 | 222,247 | - | 2.6 | 5,554 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 4.41 per share. | 19 Feb 2025 | 4,326 | 220,119 | - | 4.4 | 19,091 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Dec 2024 | 2,500 | 123,195 | - | 2.3 | 5,825 | Common Stock |
| Lexeo Therapeutics Inc. | Townsend Richard Nolan | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Dec 2024 | 2,500 | 118,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Nolan Townsend Richard | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.20 per share. | 10 Dec 2024 | 2,500 | 120,695 | - | 8.2 | 20,491 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 2,500 | 121,155 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 7.82 per share. | 11 Nov 2024 | 2,500 | 120,695 | - | 7.8 | 19,557 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 11 Nov 2024 | 2,500 | 123,195 | - | 2.3 | 5,825 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Oct 2024 | 5,000 | 125,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Oct 2024 | 5,000 | 123,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 8.10 per share. | 10 Oct 2024 | 5,000 | 120,695 | - | 8.1 | 40,496 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 5,000 | 128,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 10 Sep 2024 | 5,000 | 120,695 | - | 10.7 | 53,274 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Sep 2024 | 5,000 | 125,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 11.53 per share. | 12 Aug 2024 | 5,000 | 120,695 | - | 11.5 | 57,635 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 12 Aug 2024 | 5,000 | 125,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 5,000 | 133,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.06 per share. | 10 Jul 2024 | 27,931 | 120,795 | - | 17.1 | 476,503 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.45 per share. | 10 Jul 2024 | 23,622 | 152,073 | - | 16.5 | 388,582 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2024 | 5,000 | 138,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Jul 2024 | 5,000 | 175,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.85 per share. | 10 Jul 2024 | 3,347 | 148,726 | - | 16.9 | 56,397 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.06 per share. | 10 Jul 2024 | 100 | 120,695 | - | 19.1 | 1,906 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2024 | 5,000 | 143,655 | - | - | Stock Option (right to buy) | |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 10 Jun 2024 | 5,000 | 175,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 17.29 per share. | 10 Jun 2024 | 2,962 | 172,733 | - | 17.3 | 51,213 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.18 per share. | 10 Jun 2024 | 2,038 | 170,695 | - | 18.2 | 37,051 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.33 per share. | 13 May 2024 | 5,000 | 175,695 | - | 2.3 | 11,650 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2024 | 5,000 | 148,655 | - | - | Stock Option (Right to Buy) | |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 13.22 per share. | 13 May 2024 | 5,000 | 170,695 | - | 13.2 | 66,093 | Common Stock |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 262,500 | 262,500 | - | - | Stock Option (Right to Buy) | |
| Lexeo Therapeutics Inc. | Richard Nolan Townsend | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 43,750 | 170,695 | - | 0 | Common Stock |